Avacta
Lead therapeutic asset AVA6000 enters the clinicHUTCHMED
Strategic collaboration for Tazverik in Greater ChinaAllergy Therapeutics
Biomarker data confirm VLP Peanut hypoallergenicityScancell
CTA approval confirms H221 COVIDITY Phase I startANGLE
First custom CTC assay development contractRedx Pharma
RXC004 2mg dose selected for Phase II trialsRedx Pharma
Rezurock approval has positive read across for RedxAllergy Therapeutics
Strong FY21 trading, but pipeline set to drive futureHUTCHMED
ASCO 2021: Moving towards combinationsHUTCHMED
Hong Kong listing number 13 is a potent symbol